SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77641.05
875.13 (1.14%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	CORONA Remedies Ltd.	Q V+ PT	12,654 Small Cap	2,098.15 (1.41%)	68.45	16.96	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	Acutaas Chemicals Ltd.	Q V+ PT	27,092 Small Cap	3,317.30 (0.25%)	68.17	15.53	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Neuland Laboratories Ltd.	Q V+ PT	24,197 Small Cap	19,253.05 (2.09%)	66.64	12.97	16.64	37.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Innova Captab Ltd.	Q V PT	5,479 Small Cap	970.90 (1.40%)	65.47	6.18	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Metropolis Healthcare Ltd.	Q V PT	12,152 Small Cap	591 (0.85%)	63.95	8.03	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Viyash Scientific Ltd.	Q V PT	11,064 Small Cap	256.45 (1.26%)	62.41	4.09	20.23	2.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	Gufic Biosciences Ltd.	Q V PT	3,881 Small Cap	383.50 (-0.92%)	61.46	5.84	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Rainbow Childrens Medicare Ltd.	Q V PT	14,920 Small Cap	1,498 (1.98%)	59.67	8.85	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Jupiter Life Line Hospitals Ltd.	Q V PT	10,761 Small Cap	325.20 (-0.93%)	56.23	6.69	21.03	54.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	Dr. Lal Pathlabs Ltd.	Q V PT	30,280 Small Cap	1,881.75 (4.18%)	55.58	11.77	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Syngene International Ltd.	Q V+ PT	16,520 Small Cap	413.40 (1.01%)	54.18	3.54	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	Mankind Pharma Ltd.	Q V PT	1,08,129 Mid Cap	2,604.55 (-0.52%)	53.07	6.61	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Narayana Hrudayalaya Ltd.	Q V PT	42,358 Mid Cap	2,080.75 (0.39%)	52.58	9.34	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	Thyrocare Technologies Ltd.	Q V+ PT	9,229 Small Cap	583 (0.54%)	52.35	14.66	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Strides Pharma Science Ltd.	Q V+ PT	9,604 Small Cap	1,051.05 (0.87%)	52.3	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Granules India Ltd.	Q V+ PT	20,957 Small Cap	846.25 (0.06%)	52.01	5.11	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Concord Biotech Ltd.	Q V PT	13,121 Small Cap	1,294.45 (3.21%)	50.29	6.5	11.33	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	Poly Medicure Ltd.	Q V PT	16,710 Small Cap	1,673 (1.48%)	49.73	5.47	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Bliss GVS Pharma Ltd.	Q V+ PT	4,785 Small Cap	463.70 (2.95%)	49.4	4.18	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	Emcure Pharmaceuticals Ltd.	Q V PT	35,881 Small Cap	1,886.55 (-0.27%)	48.95	9.67	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Shilpa Medicare Ltd.	Q V+ PT	11,839 Small Cap	604.75 (-0.09%)	48.65	4.57	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Bajaj Healthcare Ltd.	Q V PT	1,083 Small Cap	326.65 (1.52%)	47.04	1.98	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Morepen Laboratories Ltd.	Q V PT	3,030 Small Cap	56.56 (2.30%)	45.86	2.44	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	Glenmark Pharmaceuticals Ltd.	Q V+ PT	61,658 Mid Cap	2,258.85 (3.38%)	45.28	5.87	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Shree Ganesh Remedies Ltd.	Q V PT	798 Small Cap	622.40 (0.15%)	44.89	4.89	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Blue Jet Healthcare Ltd.	Q V PT	10,836 Small Cap	586.65 (2.47%)	43.73	5.02	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	44,744 Mid Cap	2,614 (-1.03%)	43.19	19.6	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	Artemis Medicare Services Ltd.	Q V+ PT	4,388 Small Cap	300.90 (8.55%)	42.42	5.05	21.41	79.02	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,860 Small Cap	4,734.85 (0.41%)	42.11	24.04	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	RPG Life Sciences Ltd.	Q V+ PT	4,765 Small Cap	2,899.80 (0.65%)	41.37	7.87	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	300.90	8.55%
Suven Life Sciences	309.10	5.05%
Divis Laboratories	7,781.20	4.86%
SMS Pharmaceuticals	397.50	4.36%
Dr. Lal Pathlabs	1,881.75	4.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Hester Biosciences	2,460.10	-2.57%
Fischer Medical	35.99	-2.31%
3B Blackbio Dx	1,275	-1.63%
Fermenta Biotech	450	-1.37%
Indraprastha Medical	363.50	-1.29%

News about Top Pharma Companies in India

Jul, 2026

Glenmark Pharmaceuticals rises as its arm launches Sugammadex Injection

Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC

Jul, 2026

Glenmark Pharmaceuticals’ arm launches Sugammadex Injection

Glenmark’s Sugammadex Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION Injection, 100 mg/mL of Merck Sharp & Dohme LLC

Jul, 2026

Dr. Lal Pathlabs - Quaterly Results

The company witnessed a 19.31% growth in the revenue at Rs. 7644.00 millions for the quarter ended June 2026 as compared to Rs. 6407.00 millions during the year-ago period.The company has announced a 28.31% increase in its profits to Rs . 1659.00 millions for the quarter ended June 2026 compared to Rs. 1293.00 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2684.00 millions from 2097.00 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	7644.00	6407.00	19.31	7644.00	6407.00	19.31	26476.00	23516.00	12.59
Other Income	299.00	263.00	13.69	299.00	263.00	13.69	1127.00	1115.00	1.08
PBIDT	2684.00	2097.00	27.99	2684.00	2097.00	27.99	8664.00	7770.00	11.51
Interest	61.00	45.00	35.56	61.00	45.00	35.56	220.00	215.00	2.33
PBDT	2623.00	2052.00	27.83	2623.00	2052.00	27.83	8143.00	7555.00	7.78
Depreciation	400.00	328.00	21.95	400.00	328.00	21.95	1541.00	1342.00	14.83
PBT	2223.00	1724.00	28.94	2223.00	1724.00	28.94	6602.00	6213.00	6.26
TAX	564.00	431.00	30.86	564.00	431.00	30.86	1520.00	1240.00	22.58
Deferred Tax	-9.00	22.00	-140.91	-9.00	22.00	-140.91	14.00	-393.00	-103.56
PAT	1659.00	1293.00	28.31	1659.00	1293.00	28.31	5082.00	4973.00	2.19
Equity	1676.00	838.00	100.00	1676.00	838.00	100.00	1676.00	836.00	100.48
PBIDTM(%)	35.11	32.73	7.28	35.11	32.73	7.28	32.72	33.04	-0.96

Jul, 2026

Acutaas Chemicals - Quaterly Results

The Turnover for the quarter ended June 2026 of Rs. 3224.09 millions increase by 56.53% from Rs. 2059.71 millions.Net profit for the quarter ended June 2026 increased significantly by 70.00% to Rs. 758.96 millions from Rs. 446.46 millions.Operating profit for the quarter ended June 2026 rose to 1141.53 millions as compared to 670.09 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3224.09	2059.71	56.53	3224.09	2059.71	56.53	13237.92	9898.35	33.74
Other Income	44.76	160.20	-72.06	44.76	160.20	-72.06	458.78	183.36	150.21
PBIDT	1141.53	670.09	70.35	1141.53	670.09	70.35	5288.83	2434.78	117.22
Interest	11.18	6.20	80.32	11.18	6.20	80.32	30.77	58.57	-47.46
PBDT	1130.35	663.89	70.26	1130.35	663.89	70.26	5258.06	2376.21	121.28
Depreciation	90.20	74.62	20.88	90.20	74.62	20.88	330.32	240.45	37.38
PBT	1040.15	589.27	76.52	1040.15	589.27	76.52	4927.74	2135.76	130.73
TAX	281.19	142.81	96.90	281.19	142.81	96.90	1265.99	540.29	134.32
Deferred Tax	25.87	15.53	66.58	25.87	15.53	66.58	111.09	70.58	57.40
PAT	758.96	446.46	70.00	758.96	446.46	70.00	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	35.41	32.53	8.83	35.41	32.53	8.83	39.95	24.60	62.42

Jul, 2026

Thyrocare Tech. - Quaterly Results

The sales figure stood at Rs. 2256.60 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 26.14% as compared to Rs. 1788.90 millions during the year-ago period.Good Net Profit growth of 39.17% reported above the corresponding previous quarter figure of Rs. 360.50 millions to Rs. 501.70 millioins.OP of the company witnessed a marginal growth to 791.20 millions from 604.80 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	2256.60	1788.90	26.14	2256.60	1788.90	26.14	7742.70	6331.00	22.30
Other Income	35.10	39.60	-11.36	35.10	39.60	-11.36	133.90	133.40	0.37
PBIDT	791.20	604.80	30.82	791.20	604.80	30.82	2697.20	2003.60	34.62
Interest	12.60	6.20	103.23	12.60	6.20	103.23	21.80	26.30	-17.11
PBDT	778.60	598.60	30.07	778.60	598.60	30.07	2615.70	1977.30	32.29
Depreciation	112.30	89.50	25.47	112.30	89.50	25.47	511.70	465.20	10.00
PBT	666.30	509.10	30.88	666.30	509.10	30.88	2104.00	1512.10	39.14
TAX	164.60	148.60	10.77	164.60	148.60	10.77	615.90	554.30	11.11
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	43.00	76.60	-43.86
PAT	501.70	360.50	39.17	501.70	360.50	39.17	1488.10	957.80	55.37
Equity	1591.70	529.90	200.38	1591.70	529.90	200.38	1591.70	529.90	200.38
PBIDTM(%)	35.06	33.81	3.71	35.06	33.81	3.71	34.84	31.65	10.07

Jul, 2026

Rainbow Children’s Medicare informs about ESG rating

Pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Rainbow Children’s Medicare has informed that CRISIL ESG Rating & Analytics (‘CRISIL ESG’) has on a voluntary basis assessed the overall Environmental, Social and Governance (ESG) and has assigned an ESG rating of 61 and a Core ESG rating of 73, based on disclosures for FY 2025-26, on July 22, 2026. The ESG rating of 61 reflects an improvement from ‘Adequate’ to ‘Strong’ ESG rating assigned to the Company for FY 2024-25 and FY 2023-24. The Company has not engaged CRISIL ESG for ESG Ratings. CRISIL ESG has independently prepared the report based on data pertaining to FY 2025-26 for the Company available in public domain.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Biocon Ltd.	70,452 Crore
2	Jubilant Pharmova Ltd.	15,366 Crore
3	Healthcare Global Enterprises Ltd.	10,135 Crore
4	Onesource Specialty Pharma Ltd.	19,809 Crore
5	Senores Pharmaceuticals Ltd.	6,108 Crore
6	Park Medi World Ltd.	11,997 Crore
7	Fortis Healthcare Ltd.	71,393 Crore
8	Aster DM Quality Care Ltd.	70,919 Crore
9	Wockhardt Ltd.	30,660 Crore
10	Rubicon Research Ltd.	25,392 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,668	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,782	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,591	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,605	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,144	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,982	4,74,397	41.33	5.68	23.70	14.41

You have 5 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Glenmark Pharmaceuticals rises as its arm launches Sugammadex Injection

Glenmark Pharmaceuticals’ arm launches Sugammadex Injection

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Thyrocare Tech. - Quaterly Results

Rainbow Children’s Medicare informs about ESG rating

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.